(Q36681297)

15 August 2017

1 reference

title

Opioid maintenance: a comparative review of pharmacological strategies (English)

1 reference

15 August 2017

1

Jason M White

1 reference

15 August 2017

Olga V Lopatko

2

1 reference

PubMed ID

17163802

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

1

1 reference

15 August 2017

1-11

1 reference

NEURAL MECHANISMS OF ADDICTION: The Role of Reward-Related Learning and Memory

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Major increases in opioid analgesic abuse in the United States: concerns and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Abuse of prescription drugs and the risk of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Prescription opioid abuse in patients presenting for methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The place of detoxification in treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Methadone--metabolism, pharmacokinetics and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Determining effective methadone doses for individual opioid-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The cost-effectiveness of methadone maintenance as a health care intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Methadone maintenance in primary care: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Methadone medical maintenance in primary care. An implementation evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

From opioid maintenance to abstinence: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The relationship between take-away methadone policies and methadone diversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The effects of methadone and its role in fatalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Low bone density in patients receiving methadone maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Comparison of methadone and slow-release morphine maintenance in pregnant addicts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Population pharmacokinetics of heroin and its major metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

The current status of heroin prescription treatment for heroin dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

National survey of end-of-life decisions made by UK medical practitioners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Effects of buprenorphine/naloxone in opioid-dependent humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Clinical efficacy of buprenorphine: comparisons to methadone and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Foreword to: buprenorphine and buprenorphine/naloxone: a guide for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Plasma concentrations during naltrexone implant treatment of opiate-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Naltrexone maintenance for heroin dependence: uptake, attrition and retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Mechanisms of fatal opioid overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

In-vitro and in-vivo characterization of a buprenorphine delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Evaluation of an injection depot formulation of buprenorphine: placebo comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

A novel cognitive-behavioral approach for treatment-resistant drug dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.1

21 January 2018

Identifiers

DOI

10.1517/14656566.8.1.1

1 reference

15 August 2017

1 reference

PubMed ID

17163802